First technology for 2024/25 MedTech Funding Mandate selected in England

NHS England launched MedTech Funding Mandate (MTFM) in 2021 to support getting innovative medical devices, diagnostics, and digital products to patients faster. The program is run by the Accelerated Access Collaborative.

Technologies should meet the following criteria to be selected for the MTFM:

• Effective: demonstrated through NICE Medical Technology Guidance (MTG) or Diagnostic Guidance (DG);
• Cost-saving within three years: NICE modelling demonstrates a net saving within three years of implementing the technology, demonstrated by a published NICE resource impact template;
• Affordable to the NHS: the budget impact should not exceed £20 million nationally in any of the first three years.

Commissioners are mandated to reimburse the MTFM technologies from their existing allocations based on actual cost. Eleven technologies are currently included in MTFM.

In August 2023, NHS England announced that the first technology to be added in 2024/25 is AposHealth, a non-invasive device worn on the feet to reduce pain and improve function in patients with knee osteoarthritis. NICE recommended AposHealth (MTG76) as a cost-saving treatment for patients unsuitable for knee replacement surgery.

NHS England will announce if more technologies are added during the Autumn; the final list will be published with the updated NHS Payment scheme (Annex A) in April 2024.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.